BRISTOL MYERS SQUIBB CO
BMYAPI behind this page
BMY Q1 2026 request
Playground key active
/api/financials?ticker=BMY&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 11,489 | 11,201 | +2.6% |
Show Product Lines breakouts |
|||
| Abraxane | 50 | 105 | -52.4% |
| Alliance and other revenues | 321 | 315 | +1.9% |
| Alliance revenues | 94 | 88 | +6.8% |
| Alliance revenues · Collaborative Arrangement | 94 | 88 | +6.8% |
| Breyanzi | 411 | 263 | +56.3% |
| Camzyos | 314 | 159 | +97.5% |
| Cobenfy | 56 | 27 | +107.4% |
| Eliquis | 4,137 | 3,565 | +16.0% |
| Gross product sales | 16,926 | 19,874 | -14.8% |
| Growth Portfolio | 6,227 | 5,563 | +11.9% |
| Krazati | 50 | 48 | +4.2% |
| Legacy Portfolio | 5,277 | 5,638 | -6.4% |
| Net product sales | 11,168 | 10,886 | +2.6% |
| Net product sales · Collaborative Arrangement | 4,148 | 3,635 | +14.1% |
| Opdivo | 2,146 | 2,265 | -5.3% |
| Opdivo Qvantig | 163 | 9 | +1711.1% |
| Opdualag | 295 | 252 | +17.1% |
| Orencia | 818 | 770 | +6.2% |
| Other Growth products | 581 | 507 | +14.6% |
| Other Legacy products | 156 | 199 | -21.6% |
| Other revenue | -15 | — | — |
| Other revenues | 227 | 227 | 0.0% |
| Pomalyst/Imnovid | 513 | 658 | -22.0% |
| Reblozyl | 555 | 478 | +16.1% |
| Revlimid | 349 | 936 | -62.7% |
| Sotyktu | 69 | 55 | +25.5% |
| Sprycel | 73 | 175 | -58.3% |
| Yervoy | 651 | 624 | +4.3% |
| Zeposia | 118 | 107 | +10.3% |
Show Geography breakouts |
|||
| Non Us | 3,444 | 3,110 | +10.7% |
| Other | 257 | 218 | +17.9% |
| US | 7,788 | 7,873 | -1.1% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 4,242 | 3,723 | +13.9% |
| Cost of Revenue | 3,421 | 3,033 | +12.8% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 2,066 | 1,788 | +15.5% |
| Selling, General & Administrative | 1,617 | 1,584 | +2.1% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 66 | 65 | +1.5% |
| Research & Development | 2,649 | 2,257 | +17.4% |
Show Nature Of Expense breakouts |
|||
| Drug Development | 1,127 | 1,081 | +4.3% |
| Other | 1,229 | 861 | +42.7% |
| Research | 293 | 314 | -6.7% |
| Acquired I P R D | 94 | 188 | -50.0% |
| Amortizationof Acquired Intangible Assets | 437 | 830 | -47.3% |
| Other Non-Operating Income (Expense) | 32 | 339 | -90.6% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | -12 | -12 | 0.0% |
| Total Costs & Expenses | 8,250 | 8,230 | +0.2% |
| Income Before Taxes | 3,240 | 2,971 | +9.1% |
| Income Tax Expense (Benefit) | 561 | 509 | +10.2% |
| Net Income | 2,678 | 2,462 | +8.8% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 1 | 6 | -83.3% |
| Retained Earnings | 2,677 | 2,456 | +9.0% |
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | 1 | 6 | -83.3% |
| Net Income | 2,677 | 2,456 | +9.0% |
| EPS (Basic) | 1.31 | 1.21 | +8.3% |
| EPS (Diluted) | 1.31 | 1.2 | +9.2% |
| Interest Expense | 411 | 494 | -16.8% |
| Interest Income | -104 | -138 | +24.6% |
| Comprehensive Income | 2,832 | 2,271 | +24.7% |
| Wtd Avg Shares (Basic) | 2,038 | 2,031 | +0.3% |
| Wtd Avg Shares (Diluted) | 2,047 | 2,040 | +0.3% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | 39 | -154 | +125.3% |
| Income Loss From Equity Method Investments | -25 | 9 | -377.8% |
| Gain Loss On Investments | -134 | 78 | -271.8% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 9,574 | 10,875 | -12.0% |
| Available For Sale Securities Debt Securities Current | 912 | 907 | +0.6% |
| Receivables Net Current | 9,368 | 10,801 | -13.3% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 163 | 170 | -4.1% |
| Inventory | 2,756 | 2,666 | +3.4% |
| Other Assets Current | 4,597 | 5,534 | -16.9% |
| Total Current Assets | 27,208 | 30,783 | -11.6% |
| Accounts Receivable | 7,946 | 9,063 | -12.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 7,658 | 7,213 | +6.2% |
| Goodwill | 21,740 | 21,737 | 0.0% |
| Deferred Tax Assets | 5,176 | 3,997 | +29.5% |
| Available For Sale Securities Debt Securities Noncurrent | 366 | 344 | +6.4% |
| Other Non-Current Assets | 6,082 | 5,866 | +3.7% |
| Total Assets | 86,476 | 92,427 | -6.4% |
| Operating Lease Right-of-Use Assets | 1,528 | 1,215 | +25.8% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 18,244 | 22,486 | -18.9% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Acquired marketed product rights | 9,384 | 12,490 | -24.9% |
| Computer Software Intangible Asset | 377 | 389 | -3.1% |
| Technology Based Intangible Assets | 1,293 | 1,622 | -20.3% |
Show Indefinite Lived Intangible Assets By Major Class breakouts |
|||
| In Process Research And Development | 7,190 | 7,985 | -10.0% |
| Current Liabilities | |||
| Debt Current | 2,308 | 3,554 | -35.1% |
| Accounts Payable | 4,234 | 4,002 | +5.8% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 2,038 | 1,762 | +15.7% |
| Other Liabilities Current | 12,616 | 16,514 | -23.6% |
| Total Current Liabilities | 19,158 | 24,070 | -20.4% |
| Current Portion of Long-Term Debt | 1,988 | 3,349 | -40.6% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 211 | 276 | -23.6% |
| Long-Term Debt | 42,152 | 46,157 | -8.7% |
| Other Non-Current Liabilities | 4,853 | 4,477 | +8.4% |
| Total Liabilities | 66,374 | 74,979 | -11.5% |
| Long-Term Debt | 44,140 | 49,506 | -10.8% |
| Operating Lease Liabilities | 1,770 | 1,356 | +30.5% |
| Accrued Income Taxes Noncurrent | 1,311 | 1,551 | -15.5% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 292 | 292 | 0.0% |
| Additional Paid-In Capital | 46,374 | 46,011 | +0.8% |
| Accumulated Other Comprehensive Income | -1,370 | -1,424 | +3.8% |
| Retained Earnings | 18,287 | 16,106 | +13.5% |
| Treasury Stock Common Value | -43,515 | -43,597 | +0.2% |
| Total Stockholders' Equity | 20,068 | — | — |
| Minority Interest | 34 | 59 | -42.4% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 20,102 | 17,448 | +15.2% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,370 | -1,424 | +3.8% |
| Additional Paid In Capital | 46,374 | 46,011 | +0.8% |
| Common Stock | 292 | 292 | 0.0% |
| Noncontrolling Interest | 34 | 59 | -42.4% |
| Retained Earnings | 18,287 | 16,106 | +13.5% |
| Treasury Stock Common | -43,515 | -43,597 | +0.2% |
| Total Liabilities & Equity | 86,476 | 92,427 | -6.4% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 594 | 1,012 | -41.3% |
| Deferred Income Taxes | 161 | 223 | -27.8% |
| Stock-Based Compensation | 146 | 144 | +1.4% |
| Impairment Of Long Lived Assets To Be Disposed Of | 412 | 5 | +8140.0% |
| Divestiture Gains And Royalties | -34 | -292 | +88.4% |
| Equity Method Investment Realized Gain Loss On Disposal | -134 | 78 | -271.8% |
| Other Non-Cash Items | 21 | 5 | +320.0% |
| Increase Decrease In Receivables | 1,687 | 15 | +11146.7% |
| Change in Inventory | 14 | -169 | +108.3% |
| Change in Accounts Payable | 409 | -85 | +581.2% |
| Increase Decrease In Other Accrued Liabilities | -3,495 | -627 | -457.4% |
| Increase Decrease In Accrued Income Taxes Payable | 187 | 54 | +246.3% |
| Increase Decrease In Other Operating Capital Net | -1,636 | -1,059 | -54.5% |
| Net Cash from Operations | 1,104 | 1,954 | -43.5% |
| Investing Activities | |||
| Proceeds From Sale And Maturity Of Available For Sale Securities | 359 | 220 | +63.2% |
| Payments To Acquire Marketable Securities | -781 | -636 | -22.8% |
| Proceeds From Sale Of Equity Securities Fv Ni | 391 | 12 | +3158.3% |
| Capital Expenditures | -347 | -260 | -33.5% |
| Divestiture And Other Proceeds | 312 | 243 | +28.4% |
| Payments To Acquire Businesses Net Of Cash Acquired | -65 | -78 | +16.7% |
| Net Cash from Investing | -131 | -499 | +73.7% |
| Financing Activities | |||
| Proceeds From Other Short Term Debt | 321 | 368 | -12.8% |
| Repayments Of Long Term Debt | -500 | — | — |
| Payments Of Dividends | -1,283 | -1,258 | -2.0% |
| Payments For Proceeds From Stock Option Exercises And Other Adjustments | -98 | -103 | +4.9% |
| Net Cash from Financing | -1,560 | -993 | -57.1% |
| Supplemental | |||
| Income Taxes Paid | 239 | 235 | +1.7% |
| Interest Paid | 473 | 624 | -24.2% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -48 | 66 | -172.7% |
| Net Change in Cash | -635 | 528 | -220.3% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 9,583 | 10,875 | -11.9% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.